THBS1 Is a Novel Serum Prognostic Factors of Acute Myeloid Leukemia
THBS1 Is a Novel Serum Prognostic Factors of Acute Myeloid Leukemia
复制标题
THBS1是急性髓系白血病新的血清预后因素
DOI：
10.3389/fonc.2019.01567
复制
发表时间：
2020-02-07
影响因子：
4.7
通讯作者：
Kong, Peiyan
中科院分区：
文献类型：
--
作者：
Zhu, Lidan;Li, Qiong;Kong, Peiyan
细胞因子和生长因子的失调是肿瘤微环境的普遍特征，解开细胞因子和生长因子在生态位中的表达谱至关重要。在这里，我们评估了AML患者和健康对照组的骨髓血清样本的细胞因子谱。使用生物素化抗体芯片获得了9名AML患者和5名健康对照血清的蛋白质表达谱。共分析了507个细胞因子和生长因子。与健康人相比，AML患者共表达了31个标志性蛋白，其中27个显著高于正常对照组，4个显著低于正常对照组。将患者分为预后良好组和预后不良组，12种标志性蛋白在两组间的表达差异有统计学意义。此外，为了确定细胞因子表达谱的准确性，我们验证并分析了116例患者和9名健康人的THBS1(凝血酶反应蛋白1)的表达。我们发现THBS1在AML患者中低表达，这可能是由启动子甲基化引起的，低THBS1患者的生存时间较短。我们的数据表明，我们成功地利用生物素化抗体芯片揭示了AML患者的差异表达蛋白质；其中，THBS1可能是AML患者治疗的潜在治疗靶点。
Dysregulation of cytokines and growth factors is a general feature of tumor microenvironment, and unraveling the expression spectrum of cytokine and growth factor in niche is of utmost importance. Here, we evaluated cytokine profiling of bone marrow serum samples in AML patients and healthy controls. Protein expression profiling of serum from nine AML patients and five healthy controls was obtained using a biotinylated antibody chip. A total of 507 cytokines and growth factors were analyzed. Compared with healthy people, AML patients expressed 31 signature proteins, among which, 27 were significantly higher expressed and 4 proteins were lower. When patients were divided into favorable and poor prognosis, 12 signature proteins were significantly differentially expressed between these two groups. Furthermore, in order to identify the accuracy of cytokine expression profiles, we verified and analyzed the expression of THBS1 (Thrombospondin 1) in 116 patients and 9 healthy people. We found that THBS1 was lowly expressed in AML patients, which might be induced by promoter methylation, and patients with low THBS1 possessed shorter survivor time. Our data indicated that we successfully unveil differentially expressed proteins in AML patients using a biotinylated antibody chip; among them, THBS1 may be a potential therapeutic target for AML patients' treatment.